doi: 10.1093/labmed/11.12.778pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/11.12.780pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/11.12.784pmid: N/A
Abstract Serum drug concentrations are interpreted clinically in terms of reference or therapeutic ranges. Criteria for establishing these ranges have not always been clearly defined. Thus, data from clinical laboratories will be more and more important in confirming the clinical interpretation of drug concentration data as more physicians request drug assays and as laboratories improve their analyses. Therapeutic drug monitoring, Drug assay, Therapeutic range This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/11.12.788pmid: N/A
Abstract A comprehensive quality control program in therapeutic drug monitoring, as in every other area of the clinical laboratory, must concern itself with each step of the analytic process, beginning with the preparation of the patient and ending with the reporting of results to the clinician. Thus, a quality control program must include not only a daily analysis of quality control materials and participation in interlaboratory survey programs but also various other components that are essential in assuring reliable results. A discussion of each of these quality control components is presented. Quality control, Quality assurance, Therapeutic drug monitoring, Drug assays This content is only available as a PDF. © American Society of Clinical Pathologists
Anhalt, John, P.;Moyer, Thomas, P.
doi: 10.1093/labmed/11.12.797pmid: N/A
Abstract Gas-liquid chromatography and liquid chromatography are powerful analytic methods for the qualitative and quantitative analyses of complex mixtures. These methodologies are readily adapted to therapeutic drug monitoring; they not only provide accurate quantitation of specific drugs in clinical specimens, but also allow detection, identification and quantitation of drugs and drug metabolites that are not known beforehand to be present in a particular specimen. Sample preparation and sequential analysis are the timeconsuming elements in chromatographic techniques. These two factors limit the practical applications of chromatography to situations in which relatively small numbers of specimens are tested. Because of the low cost of reagents and the analytic flexibility of chromatography, however, advances in automation of sample processing and data reduction will make chromatography more attractive for larger work loads. A critical review of the applications of gas-liquid chromatography and liquid chromatography for routine analyses of therapeutic drugs in clinical laboratories is presented. The drug groups considered include antiepileptics, cardioactive drugs, psychoactive drugs, antihypertensives and antibiotics. Drug analysis, Automation, Gasliquid chromatography, Liquid chromatography, Antiepileptics, Cardioactive drugs, Psychoactive drugs, Antihypertensives, Antibiotics This content is only available as a PDF. © American Society of Clinical Pathologists
Nakamura, Robert, M.;Dito, William, R.
doi: 10.1093/labmed/11.12.807pmid: N/A
Abstract A review of the principles and current status of nonradioisotopic immunoassays in the context of therapeutic drug monitoring application is presented. The methods discussed include 1) light scattering, both nephelometric and particle aggregation; 2) fluorescence; 3) immunoenzyme; and 4) chemiluminescence. Basically, all of these methods have demonstrated acceptable sensitivity and replicability for application to drugs of current interest to therapeutic drug monitoring. Each system presents advantages and disadvantages which must be reviewed by the user before making a decision for individual laboratory application. Immunoassay, Particle immunoassay, Fluoroimmunoassay, Nephelometric immunoassay, Therapeutic drug monitoring This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/11.12.818pmid: N/A
Abstract The explosive advance of technology has made drug assays widely available for therapeutic monitoring, but the understanding of such data has not progressed as rapidly. Therefore, the pathologist should provide consultation to the clinician when apparently inappropriate drug monitoring data are obtained. This task can be approached in a systematic fashion by answering the following four questions of a simple logic tree: 1) Is the blood drug concentration within the therapeutic range? 2) Was the sample inappropriate? 3) Are special circumstances absent in the patient? 4) Are the special circumstances reversible? Clinical consultation, Therapeutic drug range, Sampling for drug assays, Drug disposition, Pharmacokinetics This content is only available as a PDF. © American Society of Clinical Pathologists
Schoenknecht, Fritz, D.;Sherris, John, C.
doi: 10.1093/labmed/11.12.824pmid: N/A
Abstract Category A-l continuing education credit is available to anyone who studies a C/E Update series and completes a written exam. Exams can be ordered from the ASCP and will be sent to participants following the appearance of the final article of each series in LABORATORY MEDICINE. After receipt of a completed answer sheet at ASCP prior to the deadline stated on the exam, a certificate of credit will be awarded to each participant. An exam order form appears on page 817 in this issue. This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/11.12.835pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/11.12.838pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
Showing 1 to 10 of 10 Articles